

Reauthorization of the Prescription Drug User Fee Act

HEARING

Reauthorization of the Prescription Drug User Fee Act

Subcommittee on Health
Tuesday, April 17, 2007
10:00 a.m. 2123 Rayburn House Office Building

Hearing Webcast

(Any use of this recording is subject to Rule XI, 4 of the House of Representatives. See text of Rule XI, 4 as posted by the House Committee on Rules.)

Connect to the Video Webcast of this Hearing (100 kbps) or Download

Windows Media Player is required for Committee Webcasts.

Witness List & Prepared Testimony (pdf files)

Panel I

Dr. Theresa M. Mullin
Assistant Commissioner for Planning
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Panel II

Dr. Alan Goldhammer
Deputy Vice President for Regulatory Affairs
Pharmaceutical Research and Manufacturers of
America (PhRMA)
950 F Street, N.W.
Washington, D.C. 20004

Mr. James Thew
Patient Advocate
Amyotrophic Lateral Sclerosis (ALS) Association
1034 Minns Drive, Unit B

Machesney Park, IL 61115

Ms. Kay Holcombe
Senior Policy Advisor
Genzyme Corporation
1850 K Street, N.W.
Suite 650
Washington, D.C. 20006

Mr. William K. Vaughan
Senior Policy Advocate
Consumers Union
1101 17th Street, N.W., Suite 500
Washington, D.C. 20036

Mr. William Hubbard
Senior Advisor
Coalition for a Stronger FDA
202 Weaver Mine Trail
Chapel Hill, NC 27517

Hearing Transcript

Not available at this time. The printed hearing should be available within 90-120 days of the conclusion of the hearing. When available, the text of the printed hearing may be viewed at the U.S. Government Printing Office Web site.